HK1100812A1 - Composition for the prophylaxis/treatment of hbv infections and hbv- mediated diseases - Google Patents
Composition for the prophylaxis/treatment of hbv infections and hbv- mediated diseasesInfo
- Publication number
- HK1100812A1 HK1100812A1 HK07105918.1A HK07105918A HK1100812A1 HK 1100812 A1 HK1100812 A1 HK 1100812A1 HK 07105918 A HK07105918 A HK 07105918A HK 1100812 A1 HK1100812 A1 HK 1100812A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hbv
- prophylaxis
- treatment
- composition
- mediated diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10339927A DE10339927A1 (de) | 2003-08-29 | 2003-08-29 | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
PCT/EP2004/009590 WO2005023297A1 (de) | 2003-08-29 | 2004-08-27 | Zusammensetzung zur prophylaxe/therapie von hbv-infektionen und hbv-vermittelten erkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1100812A1 true HK1100812A1 (en) | 2007-09-28 |
Family
ID=34202216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07105918.1A HK1100812A1 (en) | 2003-08-29 | 2007-06-05 | Composition for the prophylaxis/treatment of hbv infections and hbv- mediated diseases |
Country Status (12)
Country | Link |
---|---|
US (2) | US20060233832A1 (zh) |
EP (1) | EP1660125B1 (zh) |
JP (1) | JP4740133B2 (zh) |
KR (2) | KR101250029B1 (zh) |
CN (1) | CN1874787B (zh) |
AU (1) | AU2004269882B2 (zh) |
BR (1) | BRPI0414026A (zh) |
CA (1) | CA2535734A1 (zh) |
DE (1) | DE10339927A1 (zh) |
ES (1) | ES2541123T3 (zh) |
HK (1) | HK1100812A1 (zh) |
WO (1) | WO2005023297A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1764369A1 (de) | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Hbv 백신 및 그의 제조 방법 |
US9052304B2 (en) | 2009-03-13 | 2015-06-09 | Terrasep, Llc | Methods and apparatus for centrifugal liquid chromatography |
US9393299B2 (en) * | 2009-08-07 | 2016-07-19 | Transgene S.A. | Composition for treating HBV infection |
US10076570B2 (en) | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
US9238679B2 (en) * | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
MA34956B1 (fr) | 2011-02-12 | 2014-03-01 | Globeimmune Inc | Therapeutique a base de levure pour infection chronique par l'hepatite b |
EA029137B1 (ru) | 2011-04-21 | 2018-02-28 | Ионис Фармасьютикалз, Инк. | Модулирование экспрессии вируса гепатита в (hbv) |
EP2629096A1 (en) * | 2012-02-20 | 2013-08-21 | Roche Diagniostics GmbH | HBV immunocomplexes for response prediction and therapy monitoring of chronic HBV patients |
KR101646830B1 (ko) * | 2013-05-31 | 2016-08-08 | (주)셀트리온 | B형 간염 바이러스를 중화시킬 수 있는 결합 분자 |
RU2733496C2 (ru) * | 2015-03-16 | 2020-10-02 | Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) | Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний |
CN113058033B (zh) * | 2019-12-16 | 2024-07-09 | 远大赛威信生命科学(南京)有限公司 | 一种用于预防和治疗乙型肝炎的药物组合物及其用途 |
WO2023143445A1 (zh) * | 2022-01-25 | 2023-08-03 | 厦门大学 | 用于治疗hbv感染及相关疾病的表位肽及抗体 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196194A (en) * | 1979-05-24 | 1993-03-23 | The Regents Of The University Of California | Vaccines containing Hepatitis B S-protein |
EP0389983A3 (en) * | 1989-03-31 | 1991-01-16 | Abbott Laboratories | Monoclonal antibodies to pres2 and pres1 polypeptides of the hepatitis b viral envelope |
PT97632A (pt) * | 1990-05-11 | 1992-03-31 | Scripps Clinic Res | Processo de obtencao de polipeptidos relacionados com a proteina do antigenio de superficie do virus da hepatite b e de vacinas que os contem |
CA2041772A1 (en) * | 1990-05-11 | 1991-11-12 | Larry T. Mimms | Monoclonal antibodies to pres2 and pres1 polypeptide of the hepatitis b viral envelope |
EP0491077A1 (en) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
IL101653A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Multiple hepatitis b virus surface proteins which form particles |
EP0533263A3 (en) * | 1991-09-20 | 1994-06-08 | Merck & Co Inc | A multivalent hepatitis b virus vaccine |
US6133244A (en) * | 1993-10-22 | 2000-10-17 | Institut Pasteur | Method for immunization against hepatitis B |
ZA973367B (en) * | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
GB9608626D0 (en) * | 1996-04-25 | 1996-07-03 | Univ College Of London | Hepatitis b monoclonal antibodies |
EP1234040A2 (en) * | 1999-12-03 | 2002-08-28 | Innogenetics N.V. | Hbv sequences |
JP2001294599A (ja) * | 2000-04-12 | 2001-10-23 | Sekisui Chem Co Ltd | 組み換えb型肝炎ウィルス表面抗原 |
RU2286172C2 (ru) * | 2000-08-17 | 2006-10-27 | Трипеп Аб | Вакцины, содержащие рибавирин, и способы их использования |
RU2233672C1 (ru) * | 2003-03-31 | 2004-08-10 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Комбинированная вакцина для иммунопрофилактики вирусного гепатита в и д, столбняка и дифтерии |
RU2233673C1 (ru) * | 2003-03-31 | 2004-08-10 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Комбинированная вакцина для иммунопрофилактики коклюша, дифтерии, столбняка и вирусного гепатита в и д |
-
2003
- 2003-08-29 DE DE10339927A patent/DE10339927A1/de not_active Ceased
-
2004
- 2004-08-27 BR BRPI0414026-5A patent/BRPI0414026A/pt not_active IP Right Cessation
- 2004-08-27 KR KR1020067004038A patent/KR101250029B1/ko not_active IP Right Cessation
- 2004-08-27 ES ES04764564.3T patent/ES2541123T3/es not_active Expired - Lifetime
- 2004-08-27 CN CN2004800317444A patent/CN1874787B/zh not_active Expired - Fee Related
- 2004-08-27 AU AU2004269882A patent/AU2004269882B2/en not_active Ceased
- 2004-08-27 CA CA002535734A patent/CA2535734A1/en not_active Abandoned
- 2004-08-27 JP JP2006524340A patent/JP4740133B2/ja not_active Expired - Fee Related
- 2004-08-27 WO PCT/EP2004/009590 patent/WO2005023297A1/de active Application Filing
- 2004-08-27 EP EP04764564.3A patent/EP1660125B1/de not_active Expired - Lifetime
- 2004-08-27 KR KR1020127003977A patent/KR20120026138A/ko not_active Application Discontinuation
-
2006
- 2006-02-28 US US11/365,210 patent/US20060233832A1/en not_active Abandoned
-
2007
- 2007-06-05 HK HK07105918.1A patent/HK1100812A1/xx not_active IP Right Cessation
-
2011
- 2011-07-07 US US13/177,860 patent/US20110263822A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1660125A1 (de) | 2006-05-31 |
BRPI0414026A (pt) | 2006-10-24 |
JP2007504112A (ja) | 2007-03-01 |
US20060233832A1 (en) | 2006-10-19 |
CN1874787B (zh) | 2012-09-19 |
CN1874787A (zh) | 2006-12-06 |
JP4740133B2 (ja) | 2011-08-03 |
KR20070019632A (ko) | 2007-02-15 |
AU2004269882B2 (en) | 2010-02-18 |
DE10339927A1 (de) | 2005-03-24 |
EP1660125B1 (de) | 2015-05-06 |
KR101250029B1 (ko) | 2013-04-09 |
KR20120026138A (ko) | 2012-03-16 |
AU2004269882A1 (en) | 2005-03-17 |
ES2541123T3 (es) | 2015-07-16 |
US20110263822A1 (en) | 2011-10-27 |
WO2005023297A1 (de) | 2005-03-17 |
CA2535734A1 (en) | 2005-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1100812A1 (en) | Composition for the prophylaxis/treatment of hbv infections and hbv- mediated diseases | |
EP1575480A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM | |
EP1578367A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES | |
EP1572116A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES | |
EP1576137A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM | |
GB0125222D0 (en) | Composition for the treatment of microbial infections | |
IL182643A0 (en) | Novel composition and methods for the treatment of immune related diseases | |
WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1560593A4 (en) | NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES | |
IL161070A0 (en) | Compositions for the treatment of infectious diseases | |
EP1711197A4 (en) | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS | |
EP1594444A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF STAPHYLOCOCCAL INFECTIONS OR OTHER BACTERIAL INFECTIONS | |
IL178094A0 (en) | Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions | |
PL1638938T3 (pl) | Związki, kompozycje i sposoby do leczenia i zapobiegania infekcjom ortopokswirusami i powiązanym chorobom | |
GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
EP1680145A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
GB0329254D0 (en) | Treatment of viral infections | |
EP1651255A4 (en) | TOPICAL VETERINARY COMPOSITIONS AND METHODS OF TREATING AND PREVENTING INFECTIONS | |
PL371281A1 (en) | Methods and compositions for the treatment of eye diseases | |
HUP0401392A3 (en) | Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response | |
EP1578373A4 (en) | NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM | |
EP1740221A4 (en) | METHOD AND COMPOSITIONS FOR TREATING POLYCYSTIC DISEASES | |
IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
GB0329958D0 (en) | Treatment of viral infections | |
EP1562587A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180825 |